Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

[Retracted]Gambigyeongsinhwan(4) Reduces Body Weight and Hepatic Lipid Accumulation in High Fat Diet-Fed Obese Male C57BL/6N Mice

[논문철회]고지방식이 마우스 비만모델에서 감비경신환(4)에 의한 체중감량과 간 지방축적의 변화

  • Lee, Hye Rim (Department of Formula Science and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dongeui University) ;
  • Ahn, Ye Ji (Department of Formula Science and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dongeui University) ;
  • Lee, Hee Young (Department of Formula Science and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dongeui University) ;
  • Lee, Hyung Hee (Department of Life Sciences, Mokwon University) ;
  • Kim, Dong Yeo (Department of Life Sciences, Mokwon University) ;
  • Yoon, Mi Chung (Department of Life Sciences, Mokwon University) ;
  • Lee, Yong Tae (Department of Oriental Physiology, College of Korean Medicine, Dongeui University) ;
  • Shin, Soon Shik (Department of Formula Science and Research Institute of Korean Medicine for Diabetes and Obesity, College of Korean Medicine, Dongeui University)
  • 이혜림 (동의대학교 한의과대학 방제학교실 및 한방당뇨비만연구소) ;
  • 안예지 (동의대학교 한의과대학 방제학교실 및 한방당뇨비만연구소) ;
  • 이희영 (동의대학교 한의과대학 방제학교실 및 한방당뇨비만연구소) ;
  • 이형희 (목원대학교 바이오건강학부) ;
  • 김동여 (목원대학교 바이오건강학부) ;
  • 윤미정 (목원대학교 바이오건강학부) ;
  • 이용태 (동의대학교 한의과대학 생리학교실) ;
  • 신순식 (동의대학교 한의과대학 방제학교실 및 한방당뇨비만연구소)
  • Received : 2013.02.06
  • Accepted : 2013.02.20
  • Published : 2013.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

We investigated the effects of gambigyeongsinhwan(GGH)(4) on body weight and non-alcoholic fatty liver disease(NAFLD) examined whether blood total cholesterol, LDL-cholesterol, free fatty acid and triglyceride levels and hepatic lipid accumulation are inhibited by it in high fat diet-fed obese male mice. 8 weeks old, high fat diet-fed obese male mice were divided into 5 groups: C57BL/6N normal, control, GGH(4)-1, GGH(4)-2 and GGH(4)-3. After mice were treated with GGH(4) for 8 weeks, we measured body weight gain, food intake, feeding efficiency ratio, fat weight, plasma ALT, leptin and lipid levels. We also did histological analysis for liver and fat on the mice. Compared with controls, GGH(4)-treated mice had lower body weight gain and adipose tissue weight, the magnitudes of which were prominent in GGH(4)-2. Compared with controls, GGH(4)-treated mice had lower feeding efficiency ratio and blood leptin level, the magnitudes of which was prominent in GGH(4)-2. Compared with controls, GGH(4)-treated mice had lower blood plasma total cholesterol, LDL-cholesterol, free fatty acid and triglyceride levels. Compared with controls, GGH(4)-2 treated mice had lower blood plasma ALT concentration. Consistent with their effects on body weight gain, the size of adipocytes were significantly decreased by GGH(4), whereas the adipocyte number per unit area was significantly increased, suggesting that GGH(4) decreased the number of large adipocytes. Hepatic lipid accumulation was decreased by GGH(4). In conclusion, these results suggest that GGH(4) exhibits anti-obesity effects through the modulation of feeding efficiency ratio and plasma obesity parameters. Moreover, it seems that GGH(4) also contributes to improve NAFLD through the regulation of plasma ALT and hepatic triglyceride accumulation.

Keywords

References

  1. Neuschwander-Tetri, B.A., Caldwell, S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 37(5):1202-1219, 2003. https://doi.org/10.1053/jhep.2003.50193
  2. 식품의약품안전청 영양정책관 영양정책과. 건강한 간을 원한다면 탄수화물 섭취를 줄이세요-비알콜성 지방간, 탄수화물 및 당류 섭취량과 연관성 높아-. 2013년 1월 30일 보도 (http://www.kfda.go.kr).
  3. Byrne, C.D., Olufadi, R., Bruce, K.D., Cagampang, F.R., Ahmed, M.H. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 116(7):539-564, 2009. https://doi.org/10.1042/CS20080253
  4. Lazo, M., Clark, J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28(4):339-350, 2008. https://doi.org/10.1055/s-0028-1091978
  5. Fan, J.G., Farrell, G.C. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50(1):204-210, 2009. https://doi.org/10.1016/j.jhep.2008.10.010
  6. Targher, G., Bertolini, L., Rodella, S., Tessari, R., Zenari, L., Lippi, G., Arcaro, G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30(8):2119-2121, 2007. https://doi.org/10.2337/dc07-0349
  7. Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., Kawahito, Y., Yoshida, N., Suetsugu, A., Kato, T., Okuda, J., Ida, K., Yoshikawa, T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13(10):1579-1584, 2007. https://doi.org/10.3748/wjg.v13.i10.1579
  8. 沈映君 主編. 中藥藥理學. 第1版 第1次印刷. 北京, 人民衛生出版社, pp 645-646, 2000.
  9. 常新全, 丁麗霞 主編. 中藥活性成分分析手冊(上, 下冊). 第1版 第1次印刷. 北京, 學苑出版社, pp 1354-1360, 2002.
  10. 江蘇新醫學院 編. 中藥大辭典(上卷). 上海, 上海科學技術出版社, pp 1088-1089, 1995.
  11. 冉先德. 中華藥海(下卷). 哈爾濱, 哈爾濱出版社, pp 865-866, 1993.
  12. 甘偉松. 藥用植物學. 臺北, 國立中國醫藥硏究所, p 169, 1993.
  13. 김재길. 원색천연약물대사전(하). 서울, 남산당, p 161, 1992.
  14. 서부일. 赤楊에 關한 文獻的 考察. 한약응용학회지 3(1):67-68, 2003.
  15. 國家中醫藥管理局 中華本草 編委會 編. 中華本草(8冊). 第1版 第1次印刷. 上海, 上海科學技術出版社, pp 762-763, 1999.
  16. 오창호. 비만억제자인 $\alpha$-MSH 유사체의 합성 및 약효분석(신약 개발연구개발사업 최종보고서). 서울, 보건복지부, p 21, 2003.
  17. Garrido-Polonio, C., Garcia-Linares, M.C., Garcia -Arias, M.T., Lopez-Varela, S., Garcia-Fernandez, M.C., Terpstra, A.H., Sanchez-Muniz, F.J. Thermally oxidised sunflower-seed oil increases liver and serum peroxidation and modifies lipoprotein composition in rats. Br J Nutr. 92(2):257-265, 2004. https://doi.org/10.1079/BJN20041174
  18. Clark, J.M., Brancati, F.L., Diehl, A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98(5):960-967, 2003. https://doi.org/10.1111/j.1572-0241.2003.07486.x
  19. Westerbacka, J., Corner, A., Tiikkainen, M., Tamminen, M., Vehkavaara, S., Hakkinen, A.M., Fredriksson, J., Yki-Jarvinen, H. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47(8):1360-1369, 2004.
  20. Fraser, A., Longnecker, M.P., Lawlor, D.A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 133(6):1814-1820, 2007. https://doi.org/10.1053/j.gastro.2007.08.077
  21. Kim, W.R., Flamm, S.L., Di Bisceglie, A.M., Bodenheimer, H.C.; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47(4):1363-1370, 2008. https://doi.org/10.1002/hep.22109